Dosage of vancomycin during continuous renal replacement therapy;Dávkování vankomycinu při kontinuální náhradě funkce ledvin

Klinicka Farmakologie a Farmacie

Volumn 25, Issue 3, 2011, Pages 116-120

  Zahálková, Jana ^a,b   Strojil, Jan ^a   Petejová, Naděžda ^c   Urbánek, Karel ^a   Grundmann, Milan ^d   Kacířová, Ivana ^d  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b Hemodialyza ní odd lení nemocnice   (Czech Republic)

^c UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^d NONE   (Czech Republic)

Author keywords

Acute kidney injury; Continuous renal replacement therapy; Sepsis; Therapeutic drug monitoring; Vancomycin

Indexed keywords

POLYSULFONE; VANCOMYCIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DRUG DOSE COMPARISON; DRUG EFFICACY; HUMAN; KIDNEY INJURY; MINIMUM INHIBITORY CONCENTRATION; RECOMMENDED DRUG DOSE; SEPSIS;

EID: 84855650162     PISSN: 12127973     EISSN: 18035353     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kuang D, Verbine A, Ronco C. Pharmacokinetics and antimicrobial dosing adjustment in critically ill patients during continuous renal replacement therapy. Clinical Nephrology 2007; 67 (5): 267-284.
2. Trotman RL, Willimson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clinical Practice 2005; 41: 1159-1166.
3. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clinical Infectious Diseases 2006; 42 (Suppl 1): 35-39.
4. Moellering, RC Jr. Vancomycin: a 50-years reassessment. Clin Infect Dis 2006; 42 (Suppl 1): 3-4.
5. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clinical Infectious Diseases 2008; 46: 193-200.
6. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American society of health-system pharmacists, the Infectious diseases society of America, and the Society of infectious diseases pharmacists. Am J Health-Syst Pharm 2009; 66: 82-98.
7. Bouchard J, Soroko SB, Chertow GM, et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int 2009, 76: 422-427.
8. Murray PT, Liu KD. Acute kidney injury and critical care nephrology: management of renal replacement therapy in acute kidney injury. NephSAP 2011; 10 (3): 242-247.
9. Nakamura M, Oda S, Sadahiro T, et al. Treatment of severe sepsis and septic shock by CHDF using a PMMA membrane hemofilter as a cytokine modulator. In Suzuki H, Hirasawa H. Acute blood purification.Contributions to nephrology, vol. 166, Karger 2010: 73-82.
10. Matejovic M, Radej J. Dávkování antibiotic u kriticky nemocných s potrebou náhrady funkce ledvin - složitá teorie, empirická praxe. Postgraduální nefrologie 2011; IX (3): 41-44.
11. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative (ADQI) group. Crit Care 2004; 8: 204-212.
12. Choi G, Gomersall CH, Tian Q, Joynt GM, Freebairn R, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009; 37 (7): 2268-2282.
13. Schentag JJ. Antimicrobial action and pharmacokinetics/ pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J Chemother 1999; 11 (6): 426-439.
14. Schück O, Teplan V, Marecková O, Skibová J, Stollová M. Estimation of glomerular filtration rate based on the modification of Diet in Renal Disease equation in patients with chronic renal failure. Kidney Blood Pres Res 2005; 28 (1): 63-67.
15. Liu KD, Himmelfarb J, Paganini E, et al. Timing of initiation of dialysis in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 2006; 1: 915-919.
16. Kuang D, Verbine A, Ronco C. Pahrmacokinetics and antimicrobial dosing adjustment in critically ill patients during continuous renal replacement therapy. Clinical Nephrology 2007; 67: 267-284.
17. Uchino S, Cole L, Morimatsu H, Goldsmith D, Bellomo R. Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution. Intensive Care Med 2002; 28: 1664-1667.
18. Jun M, Lambers Heerspink HJ, Ninomiya T, et al. Intensities of renal replacement therapy in acute kidney injury: a systemic review and meta-analysis. Clin J Am Soc Nephrol 2010; 5: 956-963.
19. Kellum JA, Ronco C. Dialysis: results of RENAL-what is the optimal CRRT target dose? Nature Reviews Nephrology 2010; 6: 191-192.
20. Tonelli M, Manns B, Feller-Kopman D. Acute renal failure in the intensive care unit: a systematic review of the impact of dialytic modality on mortality and renal recovery. Am J Kidney Dis 2002; 40: 875-885.
21. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemotherapy 1988; 32: 848-852.
22. Bouman CSC, van Kan HJM, Koopmans RP, Korevaar JC, Schultz MJ, Vroom MB. Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing. Intensive Care Med 2006; 32: 2013-2019.
23. Decker BS, Kays MB, Chambers M, Kraus MA, Moe SM, Sowinski KM. Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis. Clin J Am Soc Nephrol 2010; 5: 1981-1987.